Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novo Nordisk announces Q1 financial results

Novo Nordisk announces Q1 financial results

30th April 2008

First quarter (QI) operating profits at Novo Nordisc increased by 22 per cent, the firm announced today.

Sales increased by 15 per cent in local currencies, with sales of modern insulins increasing by 33 per cent, a company statement revealed. Sales of NovoSevern increased by ten per cent, while sales of Norditropin increased by 17 per cent – although these figures were slightly lower in Danish kroner due to the depreciation of currencies.

“We are especially satisfied with the robust sales growth for our modern insulins in the major markets and the sustainable improvement in our gross margin,” said Lars Rebien Sorensen, president and chief executive officer at Novo Nordisk.

“The solid momentum in our business is maintained in the first quarter of 2008,” he added.

Novo Nordisk claims to have “the broadest diabetes product portfolio” in the industry and also works in areas such as hormone replacement therapy, growth hormone therapy and haemostasis management.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.